This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
by Zacks Equity Research
KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.
AMRNNegative Net Change LQDAPositive Net Change KROSPositive Net Change INDVNegative Net Change
biotechs
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?
by Sundeep Ganoria
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
by Sundeep Ganoria
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
REGNNegative Net Change ABBVPositive Net Change ANIPNegative Net Change
biotechs medical pharmaceuticals
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
by Sundeep Ganoria
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
REGNNegative Net Change ABBVPositive Net Change ANIPNegative Net Change HRMYPositive Net Change
biotechs medical pharmaceuticals
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
by Sundeep Ganoria
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
REGNNegative Net Change ABBVPositive Net Change ANIPNegative Net Change
biotechs medical pharmaceuticals
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
by Zacks Equity Research
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
BIIBNegative Net Change LLYPositive Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
by Zacks Equity Research
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
AMRNNegative Net Change CRMDPositive Net Change IMCRPositive Net Change INDVNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
by Zacks Equity Research
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
AMRNNegative Net Change LQDAPositive Net Change INDVNegative Net Change
biotechs
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
by Zacks Equity Research
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
ALTPositive Net Change AMRNNegative Net Change LQDAPositive Net Change INDVNegative Net Change
biotechs
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
by Zacks Equity Research
bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.
BIAFNegative Net Change
biotechnology biotechs earnings medical